Introduction: The homeostasis of magnesium (Mg) is impaired in chronic kidney disease (CKD) and it has been suggested that intestinal absorption of Mg may be affected by vitamin D status. 25-Hydroxy vitamin D or 25(OH)D deficiency is common in patients undergoing chronic hemodialysis; however the efficacy of nutritional vitamin D supplementation on Mg level in this population remains uncertain. Objectives: The aim of this study was to evaluate the effect of vitamin D treatment on Mg levels in chronic hemodialysis patients. Patients and Methods: This randomized clinical trial study was conducted on 69 chronic hemodialysis patients (mean age of 56.93 ±12.26 years) with serum 25-hydroxy vitamin D levels <30 ng/mL. The patients were randomly assigned to one of treatment groups of oral vitamin D3- 50 000 units per week (n=35; experimental group) or 500 mg calcium D3 tablets, every 12 hours (n=34; control group) for three months. At the beginning and end of the treatment period, the levels of serum 25-hydroxy vitamin D and the levels of Mg, calcium, phosphorus and intact parathyroid hormone (iPTH) were measured in two groups. Results: In both groups, serum vitamin D levels increased significantly after treatment (P<0.0001 for both groups), however after three months of treatment, in the experimental group the levels of vitamin D were significantly higher than the patients in the control group (57 ng/mL versus 28 ng/mL; P<0.0001) and the median increase of vitamin D after treatment in the experimental group was significantly higher than the control group (40 ng/mL versus 10.5; P<0.0001). Serum Mg levels before and after treatment were not significantly different between two groups (P=0.880 and P=0.434). In this study, we found no significant correlation between serum vitamin D level with serum Mg, calcium, phosphate, and parathyroid Hormone levels (P>0.05). Conclusion: Our study shows that oral vitamin D therapy can increase 25(OH)D levels in maintenance hemodialysis patients without significant alterations in serum calcium, phosphate, magnesium and parathyroid hormone during a 12-week period. Trial Registration: Registration of trial protocol has been approved by the Iranian registry of clinical trial (#IRCT20210314050698N1; https://en.irct.ir/trial/55159, local ethical code# IR.SKUMS.REC.1397.181).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.